ONCAlert | 2018 ASCO Annual Meeting

ASCO Highlights: PD-1/PD-L1; MPACT trial, AFFIRM trial

Published Online: 12:00 AM, Tue June 4, 2013
A randomized double-blind phase III trial comparing vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD plus placebo in patients with platinum-resistant ovarian cancer (PROCEED).

The primary objective is to assess PFS based on investigator assessment (RECIST v1.1) in folate receptor positive patients. Secondary objectives include overall survival, safety/tolerability, overall response rate, and disease control rate. Enrollment to the study is currently ongoing.

Exploratory analysis of nibrin in advanced ovarian cancer (AOC) patients treated in the phase III OVA-301 trial.
The results point out the potential importance of nibrin expression in the clinical outcome of patients with advanced ovarian cancer. In particular, high protein expression of nibrin seems to be associated with a worse clinical outcome. Prospective clinical trials evaluating the clinical usefulness of this marker with other standard of care treatments are warranted.


<<< View all coverage from the 2013 ASCO Meeting



<< Previous Page (Page 2)
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.